KnoWEwell Appoints Dr. Patrick Hanaway as Chief Medical Officer
KnoWEwell, the global Regenerative Whole Health benefits and services company, is proud to announce the appointment of Dr. Patrick Hanaway as its new Chief Medical Officer (CMO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250811594767/en/
Dr. Patrick Hanaway, Chief Medical Officer, KnoWEwell P.B.C.
Dr. Hanaway is a pioneer in functional medicine and the former founding director of the Cleveland Clinic Center for Functional Medicine. Dr. Hanaway brings a wealth of knowledge, expertise and focused research on evaluating the outcomes of functional medicine models of care through education and clinical care.
'Over the last eight years, I have come to know Kimberly Whittle, KnoWEwell's founder and CEO, and have been watching the organization grow and flourish. I am excited to be joining KnoWEwell at a pivotal time in its growth and look forward to implementing transformational protocols and expanding our collaborative partnership through the Regenerative Whole Health Hub, a trusted, global ecosystem, community, and marketplace.'
Under Dr. Hanaway's guidance, KnoWEwell aims to further its mission of transforming healthcare by empowering individuals, practitioners, and organizations with the Regenerative Whole Health knowledge, resources and ecosystem community to prevent harm and address the root causes of chronic disease. Dr. Hanaway's leadership will be instrumental in expanding access to affordable, evidence-based protocols to promote WELLthier Living for members worldwide.
Ms. Whittle remarked on the milestone, saying, 'Had I not seen Dr. Hanaway speak on functional medicine, my family might not have healed and KnoWEwell might not have been born. It is a great honor to have Dr. Hanaway join KnoWEwell's family as our Chief Medical Officer.'
In addition to Dr. Hanaway's notable accomplishments, he has been initiated as a Mara'akame (Indigenous healer) by the Huichol people of the Sierra Madre in Mexico. He holds community fires, leads ceremonies, and offers traditional healing sessions. Ms. Whittle adds, 'Dr. Hanaway's work aligns seamlessly with KnoWEwell's vision to connect the dots between soil, food, nutrition, lifestyle, community, people and planet health and well-being to complement KnoWEwell's goal of transforming healthcare.'
For more information and to join KnoWEwell's RWH Hub visit KnoWEwell.com.
KnoWEwell P.B.C.
KnoWEwell, P.B.C. operates the Regenerative Whole Health Hub, the trusted global digital ecosystem, community, and marketplace that bridges the knowledge, access, and insurance gaps to proactively prevent and address the root causes of chronic disease and help individuals, practitioners, nonprofits and businesses thrive. KnoWEwell also owns Natural Awakenings Publishing Corporation, the operator of the Natural Awakenings magazine franchise system. The magazine promotes natural and holistic health, and a sustainable, green lifestyle. It reaches approximately 1.3+ million monthly readers in markets across the United States.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250811594767/en/
CONTACT: Media
KnoWEwell, P.B.C.
Public Relations
855.593.9355
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: GENERAL HEALTH HEALTH INSURANCE HEALTH PRACTICE MANAGEMENT
SOURCE: KnoWEwell
Copyright Business Wire 2025.
PUB: 08/13/2025 05:06 AM/DISC: 08/13/2025 05:05 AM
http://www.businesswire.com/news/home/20250811594767/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
The global recombinant human hair keratin protein market is growing quickly as more people seek effective hair health solutions and advanced wound healing treatments, says a study published by Towards Healthcare a sister firm of Precedence Research. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The global recombinant human hair keratin protein market is on a strong growth trajectory, with revenues expected to climb into the hundreds of millions by 2034. This momentum is being fueled by a rising focus on hair health, a noticeable increase in bleeding disorder cases, and a wave of fresh investments pouring into biotechnology. Together, these factors are creating fertile ground for innovation and demand across multiple industries. Companies in North America, Asia-Pacific, and Europe are actively investing in research, driving innovations, and forming partnerships to open new market opportunities. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the recombinant human hair keratin protein market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Market Overview & Potential Recombinant human hair keratin protein is a lab-engineered protein that replicates the structure and function of natural keratin in human hair. It is produced via recombinant DNA technology, resulting in a highly controlled and pure form of keratin that differs from traditional extracts. This makes it a valuable material for applications such as wound healing and hair care. Conventional keratin extraction methods can be inconsistent and may not yield pure products, whereas recombinant production ensures greater purity and enables precise control over the protein's amino acid sequence and structure, resulting in more predictable properties. Top Countries in Recombinant Human Hair Keratin Protein Market: United States Contribution: Leading the global market with strong demand for medical-grade recombinant keratin, supported by a robust biotech ecosystem and healthcare infrastructure. Strength: Advanced R&D capabilities and regulatory support for therapeutic and regenerative applications. China Contribution: Fastest-growing market, fueled by a rapidly expanding cosmetics and personal care sector. Strength: Strong domestic production capabilities, rising consumer awareness, and increasing investment in biotech innovations. Germany Contribution: Key contributor in Europe, especially in high-purity recombinant keratin for medical and cosmetic formulations. Strength: Expertise in biotechnology and demand for premium, high-performance personal care products. France Contribution: Strong market for cosmetic applications, particularly in haircare and skincare products incorporating natural bioactive ingredients. Strength: Sophisticated beauty industry and preference for sustainable, biologically derived ingredients. India Contribution: Emerging player in both medical and cosmetic applications of recombinant keratin. Strength: Large population base, rising demand for advanced hair and skin treatments, and growing domestic manufacturing activity. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growth Potential Responsible for The Growth of The Recombinant Human Hair Keratin Protein Market? The growth of the market is driven by the growing application in the biomedical field due to its biocompatibility, ability to promote cell growth, and biodegradability, which makes it ideal for various medical uses, driving the growth. The key applications, like tissue regeneration, drug delivery systems, and wound healing, are supporting the growth of the market. Other key drivers are biotechnology research due to the growing biotechnology sector, in personal care and cosmetics, and sustainable and ethical sourcing. Increasing incidence of chronic diseases, and government initiatives in R&D in life sciences research and development. What Are the Growing Trends Associated with the Recombinant Human Hair Keratin Protein Market? The technological advancements like innovation in synthetic biology and demonstration technology for the development of new and tailored properties, and more efficient production methods. Rising demand in the cosmetic sector for the development of hair care products for improving the shine, strengthening the damaged hair, and reducing the frizz increases the demand for the product. The growing biomedical applications, like in wound healing, tissue engineering, and drug delivery, fuel the demand for the product, supporting the growth. Shift towards sustainable and ethical products, like growing demand and interest in vegan and plant-based keratins, improves the market growth of the market. Increasing awareness and adoption due to the benefits offered and availability of the products make it a preferred choice, and increase the growth. What Is the Growing Challenge in the Recombinant Human Hair Keratin Protein Market? However, the recombinant human hair keratin protein market faces challenges including production issues, consistency concerns, and consumer perceptions. Although recombinant technology provides advantages like higher purity and specific amino acid composition, it also risks problems like misfolding, aggregation, and low yields. Additionally, high production costs, especially due to specialized equipment and chemicals, can hinder market growth. Consumer preferences for natural or plant-based products, along with safety and efficacy concerns regarding keratin treatments, could also limit market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Recombinant Human Hair Keratin Protein Market in 2024? North America led the recombinant human hair keratin protein market in 2023. Growth is driven by increased investments, collaborations, key industry players, and advanced R&D activities. The US and Canada are the primary markets, with companies like Novus Biologicals, Abcam Ltd., PROGEN, and OriGene contributing significantly. US government initiatives to promote biotech research further boost the market, complemented by over 130 recombinant proteins approved by the US FDA for clinical use. In the UK, industries are exploring innovative methods to enhance hair growth, quality, and reduce hair fall using recombinant human hair keratin protein. Additionally, rising awareness about hair health is fueling demand for these products. What Made Asia Pacific Significantly Grow in The Recombinant Human Hair Keratin Protein Market in 2024? Asia-Pacific is expected to grow the fastest in the recombinant human hair keratin protein market during the forecast period. Market growth is driven by increasing research and development activities, rising government funding, a growing number of bleeding disorder cases, favorable infrastructure, and lower costs. Recombinant keratin has been shown to promote skin wound healing and improve blood clotting. In China, about 65,000 people suffer from hemophilia, while India has the second-largest number of hemophilia cases worldwide, with 136,000 patients. The demand for products that support hair growth and reduce hair loss is rapidly increasing in China, South Korea, and Japan. Companies like Tsubaki use recombinant human keratin to develop luxurious hair treatments that attract beauty-conscious consumers. Become a valued research partner with us - Recent Developments In July 2024, Yuhan Corp, a South Korean pharmaceutical company, signed a comprehensive R&D collaboration agreement with ProGen. The collaboration was made to strengthen next-generation biologics and drug development research. In April 2024, Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific. The agreement will distribute Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, reagents, and enzymes, to laboratories and research institutions across Europe. Browse More Insights of Towards Healthcare: The global GMP grade cytokines market is valued at USD 2.54 billion in 2024, expected to rise to USD 2.79 billion in 2025, and anticipated to reach approximately USD 6.48 billion by 2034. This represents a steady growth trajectory at a CAGR of 9.84% from 2025 to 2034. The global recombinant proteins market is estimated at USD 3.36 billion in 2025 and is forecasted to climb to around USD 8.08 billion by 2034, expanding at a CAGR of 10.24% over the forecast period. The recombinant lysyl endopeptidase market was valued at USD 38 million in 2023 and is projected to reach USD 67.06 million by 2034, growing at a CAGR of 5.3% between 2024 and 2034. The global hair transplant market stands at USD 7.33 billion in 2024, rising to USD 8.87 billion in 2025, with projections indicating a surge to nearly USD 49.44 billion by 2034—signaling rapid expansion. The hair treatment drug market was worth USD 1.4 billion in 2023 and is anticipated to grow to USD 2.99 billion by 2034, recording a CAGR of 7.14% during 2024–2034. The global host cell protein testing market is valued at USD 2.37 billion in 2024, estimated to increase to USD 2.56 billion in 2025, and forecasted to hit USD 5.19 billion by 2034, with an expected CAGR of 8.17% from 2025 to 2034. The global protein expression technology market is pegged at USD 2.85 billion in 2024, projected to rise to USD 3.05 billion in 2025, and likely to reach USD 5.58 billion by 2034, reflecting a CAGR of 6.94% over the forecast timeline. The global proteinase K market is valued at USD 4.82 billion in 2024, forecasted to grow to USD 5.23 billion in 2025, and set to reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% between 2025 and 2034. The global cell-free protein expression market is valued at USD 315.03 million in 2024, expected to grow to USD 342.25 million in 2025, and projected to hit USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market is calculated at USD 375.3 billion in 2024, projected to grow to USD 401.89 billion in 2025, and expected to reach USD 740.07 billion by 2034, advancing at a CAGR of 7.08% over the forecast period. Recombinant Human Hair Keratin Protein Market Key Players Abcam Limited Abbexa, Ltd. Bon Opus Biosciences Creative Diagnostics MyBioSource, Inc. Novus Biologicals OriGene PROGEN ProSpec Wuhan Huamei Biotech Co., Ltd. Regions Covered North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Apple's blood oxygen monitoring returns to its latest Apple Watches
Apple announced on Thursday it's introducing a redesigned Blood Oxygen feature for some Watch Series 8, Series 10, and Apple Watch Ultra. With this move, Apple is bringing back blood oxygen monitoring by tweaking the feature to get around the International Trade Commission's (ITC) import ban. Blood oxygen data will be measured and calculated on the user's paired iPhone, and results can be viewed in the Respiratory section of the Health app. This means users won't be able to view the data on their Apple Watch, as they'll need to do so on their iPhone. Apple says the update announced today is enabled by a recent U.S. Customs ruling, which means that the tech giant is allowed to import Apple Watches with the redesigned Blood Oxygen feature. The change doesn't affect previously sold models with the original version of the feature or units bought outside the U.S. The redesigned feature only applies to Apple Watches that were sold after the ITC import ban took effect in early 2024. These users can access the redesigned Blood Oxygen feature through an iPhone and Apple Watch software update coming on Thursday. The move comes as Apple has been in an ongoing legal dispute with medical device maker Masimo, which has accused the tech giant of stealing its pulse oximetry technology after initial talks about a potential collaboration. In 2023, Masimo secured a victory against Apple at the ITC to block imports of Apple Watches with blood oxygen monitoring, after the commission found that Apple's technology infringed upon Masimo's patents. Apple then had to remove the feature. Apple counter-sued Masimo, claiming that the company copied Apple Watch features to use in its own smartwatches. The tech giant has also filed an appeal of the ITC ban. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
10 minutes ago
- New York Post
The rare disease tennis legend Monica Seles says had her seeing double on the court
Monica Seles, the nine-time Grand Slam champ who once dominated the court with her signature two-handed style, is facing a new kind of opponent — and this one isn't standing on the other side of the net. The 51-year-old International Tennis Hall of Famer recently revealed she's been quietly battling myasthenia gravis, a rare neuromuscular disease, for the past three years. 'It took me quite some time to really absorb it, speak openly about it, because it's a difficult one,' Seles told the Associated Press. 'It affects my day-to-day life quite a lot.' Advertisement 5 Monica Seles is a Serbian–American former professional tennis player who retired in 2008. Getty Images The tennis legend broke her silence just days before the 2025 US Open kicks off in Flushing Meadows, hoping to raise awareness about the chronic condition she'd never heard of until it landed in her own court. Here's everything you need to know. What is myasthenia gravis? Advertisement It's a rare autoimmune disorder that causes muscle weakness, often affecting those that control your eyes, face, neck, arms and legs, according to the Cleveland Clinic. The condition strikes when the body's immune system turns on itself, producing antibodies that block or destroy the receptor sites your muscles need to receive signals from the brain in order to move. With fewer working receptors, the message doesn't get through — leading to a communication breakdown between brain and body. As a result, the muscles feel weak and tire out fast, even from everyday tasks. 5 Myasthenia gravis causes muscle weakness that fluctuates and worsens with activity. buraratn – Advertisement What are the symptoms of myasthenia gravis? For more than half of those with the condition, the first signs affect the eyes, often causing double vision or drooping eyelids, per the Mayo Clinic. About 15% experience early symptoms that affect their face and throat muscles, which can: Make speech slurred or soft, sometimes sounding nasally, depending on which muscles are affected. Cause trouble chewing and swallowing, making it harder to eat, drink or take pills. Change facial expressions, like turning a smile into a snarl. Advertisement Myasthenia gravis can also weaken the neck, arms and legs, making it tough to lift things, walk steadily or even hold your head up. Seles first noticed that something was wrong when symptoms started showing up on the court. 5 Seles will make an appearance at the 2025 US Open to raise awareness about myasthenia gravis. Getty Images for American Express 'I would be playing with some kids or family members, and I would miss a ball. I was like, 'Yeah, I see two balls.' These are obviously symptoms that you can't ignore,' she told the AP. Then came the muscle weakness. 'Just blowing my hair out … became very difficult,' the tennis champ said. The weakness usually worsens the more you use the affected muscles but can improve with rest, which can sometimes make diagnosis difficult. 'Patients can present with fatigue and then healthcare providers have no idea what to do with that,' Dr. Beth Stein, director of neuromuscular diseases at St. Joseph's Health in New Jersey, told The Athletic. Who's at risk for myasthenia gravis? Advertisement It can strike anyone, but it's most often diagnosed in women under 50 and men over 65, according to the Myasthenia Gravis Foundation of America. It's also slightly more common in people of African descent, though it affects all racial and ethnic backgrounds. 5 Drooping eyelids and a weakened smile are common symptoms of myasthenia gravis, often in the early stages of the disease. LIGHTFIELD STUDIOS – While still considered rare — affecting roughly 37 out of every 100,000 Americans — cases are on the rise. Experts believe this is at least partly because people are living longer lifespans and better tools have been developed to diagnose it. What's the outlook for someone with myasthenia gravis? Advertisement There's no cure, but the condition can usually be managed with treatment, especially if it's detected early, according to Johns Hopkins Medicine. Treatment may include medications that suppress the immune system or intravenous immunoglobulin, a blood product that helps reduce the attack on the nervous system. 5 Seles was diagnosed with the autoimmune disease three years ago. GC Images Advertisement Doctors might also remove the thymus gland surgically, which can sometimes improve symptoms by altering the immune response. Another option is plasmapheresis, a procedure that filters out abnormal antibodies from the blood and replaces them with healthy ones from donors. For Seles, every day is about adapting. 'Some days are very extreme,' she told the AP. Other days, she plays tennis, pickleball and walks her dogs. Advertisement 'As I tell kids that I mentor: 'You've got to always adjust. That ball is bouncing, and you've just got to adjust,'' Seles said. 'And that's what I'm doing now.' Is myasthenia gravis fatal? Generally, no. Most people with myasthenia gravis have a normal life expectancy, but in rare cases, it can cause life-threatening complications. That includes myasthenic crisis, a severe weakening of the muscles that control breathing, which can lead to respiratory failure and other medical emergencies In such cases, a ventilator may be needed until muscle strength improves with treatment.
